Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Angle PLC (AIM:AGL) Analysis of CTC-DNA and ctDNA using Illumina assay
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
Immupharma PLC (LON:IMM) Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.
Genedrive PLC (AIM:GDR) Genedrive® CYP2C19-ID Kit performance published
Superior performance to laboratory test and alternative available point of care platforms
Novacyt S.A. (AIM: NCYT) London Vet Show: Launch of animal multiplex assays
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Genedrive (AIM:GDR) shares fall 10% following CEO departure
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
Genedrive PLC (AIM: GDR) NICE recommends CYP2C19-ID Kit in final guidance
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
Genedrive PLC (AIM:GDR) Breakthrough Device Designation from the U.S. FDA
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1
Novacyt S.A. (LON:NCYT) Settlement of the dispute with the DHSC
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Genedrive PLC (AIM:GDR) Initial orders of the Genedrive MT-RNR1 Products
Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
Angle PLC (AIM:AGL OTCQX:ANPCY) Study of ovarian cancer CTCs using Parsortix
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
Genedrive PLC (AIM:GDR) Proposed REX Retail Offer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the